A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer

Trial Profile

A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs IAB 2M (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors ImaginAb Inc
  • Most Recent Events

    • 02 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 06 Jan 2016 According to an ImaginAb media release, the results will be presented at the Genitourinary (GU) Cancers Symposium 2016.
    • 06 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to the results published in an ImaginAb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top